Pharma Update

Hematology: Shifting the standard of care in CLL, DLBCL, and FL chemotherapy Chronic Lymphocytic Leukemia (CLL) Diffuse Large B cell Lymphoma (DLBCL) Follicular Lymphoma (FL) Roche 1997 Evolution MabThera of SoC: 1L R/R 1L R/R 3L+ 1L 2L+ 3L+ Rituximab chemo clb benda CHOP benda chemo benda Rituxan Rituximab 2013 R+chemo R+clb R+benda R-CHOP R+benda GAZYVA obinutuzumab injection G+chemo G+clb 2019 POLIVY polatuzumab vedotin + New G+Venclexta R+Venclexta MOAS Polivy+ R-CHP Polivy+ R+benda VENCLEXTA venetoclax tablets ng mg Lunsumio Columvi 2022/23 Lunsumi COLUMVI glofitamab = approved R+chemo R+benda G+chemo G+benda Lunsumio Polivy + R-CHP (Ph lb/ll) + Columvi Polivy+ Lunsumio Lunsumio Columvi Lunsumio +lenalidomide Columvi+ GemOx Building on the standard of care with new best-in-class and/or first-in-class combinations CLL-chronic lymphocytic leukemia; DLBCL-diffuse large B-cell lymphoma; FL-follicular lymphoma; R=Rituxan; CHP-cyclophosphamide, doxorubicin, prednisone; R/R=relapsed/refractory; Gem Ox-gemcitabine, oxaliplatin; G-Gazyva; benda-bendamustine; SoC-standard of care; MOA-mechanism of action; Venclexta in collaboration with AbbVie 59

View entire presentation